US6409791000
© Globe Newswire
05.01.2026
NMRA
LISTED
NASDAQ
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
News Preview
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
News Preview
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
27.10.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
News Preview
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
27.10.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
News Preview
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction ...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics to Host Virtual R&D Day on October 27
News Preview
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
News Preview
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
News Preview
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
NMRA
LISTED
NASDAQ
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the federal securities laws.
Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Docume...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
NMRA
LISTED
NASDAQ
NMRA Deadline: Rosen Law Firm Urges Neumora Therapeutics, Inc. (NASDAQ: NMRA) Stockholders with Losses to Contact the Firm for Information About Their Rights in Securities Class Action First Filed by the Firm
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics, Inc. Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration st...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
NMRA
LISTED
NASDAQ
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) and reminds investors of the April 7. 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faru...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.03.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTORS: Kirby McInerney LLP Reminds Neumora Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ:NMRA): (a) common stock pursuant and/or traceable to the registration statement and prospec...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTORS: Kirby McInerney LLP Reminds Neumora Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
News Preview
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ:NMRA): (a) common stock pursuant and/or traceable to the registration statement and prospec...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
NMRA
LISTED
NASDAQ
Kessler Topaz Meltzer & Check, LLP Class Action Announcement NMRA: A Securities Fraud Class Action Lawsuit Was Filed Against Neumora Therapeutics, Inc. (NMRA)
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration st...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora’s registration statement issued in connection with Neumora’s initial public offering (“IPO”) held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plai...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
NMRA
LISTED
NASDAQ
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the federal securities laws.
Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Docum...
Themefolio
Profiler
Peergroup
© BusinessWire
08.02.2025
NMRA
LISTED
NASDAQ
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That Neumora Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora’s registration statement issued in connection with Neumora’s initial public offering (“IPO”) held on September 15, 2023, have until April 7, 2025 to seek appointm...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
NMRA
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) and reminds investors of the April 7. 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Far...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
NMRA
LISTED
NASDAQ
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA
News Preview
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s Septemb...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
News Preview
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
News Preview
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
News Preview
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
News Preview
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
News Preview
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
News Preview
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
NMRA
LISTED
NASDAQ
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
News Preview
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
